Zosyn Is Cleared for Treatment Of Nosocomial Pneumonia

ST. DAVIDS, Penn--Wyeth-Ayerst Laboratories' Zosyn (pipera-cillin/tazobactam) is now indicated for use in treating moderate to severe nosocomial pneumonia caused by piperacillin-resistant beta-lactamase-producing strains of Staphylococcus aureus. In a multicenter study of 300 patients with nosocomial pneumonia, the rate of clinical cure or improvement for Zosyn plus tobramycin was 74%, compared with 50% for cef-tazidime plus tobramycin, the company said.

Related Content:

Oncology NEWS International Vol 5 No 7

Princess Diana Helps Raise Over $1 Million for Cancer Research

Study Gives Terminal Patients Option: $18,000 or More Treatment

Proven: Colorectal Screening Cuts Deaths 50%